ArticleLife science alliance2021
Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19.
Article in Life science alliance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 43 citations in OpenAlex.
- Mechanisms and Therapeutic Potential of Targeting Mitophagy in Neurodegenerative Diseases.Molecular neurobiology · 2026Review
- Mitophagy in kidney transplantation ischemia-reperfusion injury.International urology and nephrology · 2026Review
- Fractal and Machine Learning Analyses of MALDI-TOF Mass Spectrometry Data in Glioblastoma.Computational and structural biotechnology journal · 2026Article
- Early Diagnosis of Acute Kidney Injury in Liver Transplant Patients by an Untargeted Metabolomic Approach.Analytical science advances · 2025Article
- Article
- MALDI-TOF mass spectrometry combined with machine learning algorithms to identify protein profiles related to malaria infection in human sera from Côte d'Ivoire.Malaria journal · 2025Article
- What Can Proteomics Tell us About COVID-19 Infections? Mass Spectrometry as a Tool to Find New Proteins as Biomarkers.Current protein & peptide science · 2025Review
- Recent Applications of Artificial Intelligence and Related Technical Challenges in MALDI MS and MALDI-MSI: A Mini Review.Mass spectrometry (Tokyo, Japan) · 2025Review
- Serum Proteomics of Experimental Malaria-Associated ARDS Reveals a Regulation of Acute-Phase Response Proteins.Journal of immunology research · 2025Article
- Clinical Peptidomics in Acute Leukemias: Current Advances and Future Perspectives.Journal of proteome research · 2024Review
- The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024Review
- Host heterogeneity in humoral bactericidal activity can be complement independent.Frontiers in immunology · 2024Article
- Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19.Advances in experimental medicine and biology · 2024Article
- Immune landscape and redox imbalance during neurological disorders in COVID-19.Cell death & disease · 2023Review
- Prospective on Imaging Mass Spectrometry in Clinical Diagnostics.Molecular & cellular proteomics : MCP · 2023Review
- Article
- Rapid Detection of SARS-CoV-2 Variants of Concern by Genomic Surveillance Techniques.Advances in experimental medicine and biology · 2023Article
- Predictive models for COVID-19 detection using routine blood tests and machine learning.Heliyon · 2022Review
- Spectroscopic methods for COVID-19 detection and early diagnosis.Virology journal · 2022Review
- Identification of Endogenous Peptides in Nasal Swab Transport Media used in MALDI-TOF-MS Based COVID-19 Screening.ACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infection poses a global health crisis. In parallel with the ongoing world effort to identify therapeutic solutions, there is a critical need for improvement in the prognosis of COVID-19. Here, we report plasma proteome fingerprinting that predict high (hospitalized) and low-risk (outpatients) cases of COVID-19 identified by a platform that combines machine learning with matrix-assisted laser desorption ionization mass spectrometry analysis. Sample preparation, MS, and data analysis parameters were optimized to achieve an overall accuracy of 92%, sensitivity of 93%, and specificity of 92% in dataset without feature selection. We identified two distinct regions in the MALDI-TOF profile belonging to the same proteoforms. A combination of SDS-PAGE and quantitative bottom-up proteomic analysis allowed the identification of intact and truncated forms of serum amyloid A-1 and A-2 proteins, both already described as biomarkers for viral infections in the acute phase. Unbiased discrimination of high- and low-risk COVID-19 patients using a technology that is currently in clinical use may have a prompt application in the noninvasive prognosis of COVID-19. Further validation will consolidate its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.